| Literature DB >> 32831024 |
Mehdi Mirzaei-Alavijeh1, Farzad Jalilian2, Laleh Solaimanizadeh3, Abdollah Saadatfar4, Shima Khashij1, Razieh Pirouzeh1, Farzaneh Solaimanizadeh5.
Abstract
BACKGROUND: Prostate cancer (PCa) is the second most common malignancy in men worldwide and the incidence rate of PCa has been increasing in recent years. The aim of the current study was to determine beliefs elderly men towards prostate-specific antigen (PSA) test uptake.Entities:
Keywords: Benefits; Cues to action; Elderly; Iran; Prostate specific antigen test
Mesh:
Substances:
Year: 2020 PMID: 32831024 PMCID: PMC7444239 DOI: 10.1186/s12877-020-01710-9
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
The HBM questionnaire items
| No | Construct | Item | Cronbach’s Alpha |
|---|---|---|---|
| 0.87 | |||
| 1 | PSA test uptake will help to diagnose PCa early. | ||
| 2 | PSA test uptake will help me not worry as much about PCa. | ||
| 3 | PSA test uptake will decrease my chances of dying from PCa. | ||
| 4 | PSA test uptake will help me to have a plan for the future about PCa. | ||
| 0.80 | |||
| 1 | PSA test uptake is time-consuming. | ||
| 2 | I’m afraid of diagnose PCa. | ||
| 3 | Health center is far from my house to receive PSA test uptake. | ||
| 4 | PSA test uptake is too embarrassing. | ||
| 0.70 | |||
| 1 | It is likely that I will get PCa in the future. | ||
| 2 | My chances of getting PCa in the next few years are high. | ||
| 3 | I feel I will get PCa sometime during my life. | ||
| 0.71 | |||
| 1 | PCa could seriously affect in my social life. | ||
| 2 | PCa imposes huge economic costs on my family. | ||
| 3 | PCa can kill me. | ||
| 4 | PCa is a serious disease. | ||
| 5 | Death from PCa is rare. | ||
| 0.75 | |||
| 1 | Make an appointment to have a PSA test uptake? | ||
| 2 | Find the time to have a PSA test uptake? | ||
| 3 | Get a PSA test uptake even if you are worried about the results? | ||
| 0.65 | |||
| 1 | Doctors advised me to uptake PSA. | ||
| 2 | Health care workers encourage me to PSA test uptake. | ||
| 3 | My family encourages me to PSA test uptake. | ||
| 4 | How much the PCa death in others affects you to PSA test uptake? | ||
Demographic variable and PSA test uptake
| Total | PSA test uptake | ||||
|---|---|---|---|---|---|
| N (%) | No | Yes | |||
| Age | 65.55 (3.90) | 65.31 (3.87) | 66.75 (3.84) | 0.013 | |
| Marital status | Single | 32 (10%) | 29 (10.9%) | 3 (5.6%) | 0.321 |
| Married | 288 (90%) | 237 (89.1%) | 51 (94.4%) | ||
| Economic status | Weak | 68 (21.3%) | 64 (24.1%) | 4 (7.4%) | 0.023 |
| Middle | 196 (61.2%) | 158 (59.4%) | 38 (70.4%) | ||
| Good | 56 (17.5%) | 44 (16.5%) | 12 (22.2%) | ||
| Educational level | Primary school (grades 0–6) | 121 (37.8%) | 100 (37.6%) | 21 (38.9%) | 0.004 |
| Secondary school (grades 7–9) | 109 (34.1%) | 99 (37.2%) | 10 (18.5%) | ||
| High school (grades 10–12) | 73 (22.8%) | 57 (21.4%) | 16 (29.6%) | ||
| Academic (grades 13–16) | 17 (5.3%) | 10 (3.8%) | 7 (13%) | ||
| Family member size | 1–4 number | 161 (50.3%) | 141 (53%) | 20 (37%) | 0.037 |
| More than 4 number | 159 (49.7%) | 125 (47%) | 34 (63%) | ||
| Health insurance | No | 69 (21.6%) | 62 (23.3%) | 7 (13%) | 0.104 |
| Yes | 251 (78.4%) | 204 (76.7%) | 47 (87%) | ||
| Family history of PCa | No | 298 (93.1%) | 252 (94.7%) | 46 (85.2%) | 0.018 |
| Yes | 22 (6.9%) | 14 (5.3%) | 8 (14.8%) | ||
Multiple logistic regression results for demographic variable related to PSA test uptake
| B | S.E. | Wald | P | OR | 95% C.I | |||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Step 1 | Age | 0.126 | 0.042 | 8.861 | 0.003 | 1.134 | 1.044 | 1.232 |
| Marital status | 1.116 | 0.696 | 2.572 | 0.109 | 3.053 | 0.780 | 11.941 | |
| Education | 0.849 | 0.194 | 19.188 | < 0.001 | 2.338 | 1.599 | 3.420 | |
| Economic | 0.675 | 0.287 | 5.521 | 0.019 | 1.963 | 1.118 | 3.447 | |
| Family member size | 0.909 | 0.354 | 6.583 | 0.010 | 2.481 | 1.239 | 4.967 | |
| Health insurance | 1.020 | 0.488 | 4.368 | 0.037 | 2.772 | 1.065 | 7.213 | |
| Family history of PCa | 1.886 | 0.570 | 10.939 | 0.001 | 6.595 | 2.157 | 20.171 | |
| Constant | −17.727 | 3.763 | 22.198 | < 0.001 | < 0.001 | |||
| Step 2 | Age | 0.103 | 0.040 | 6.695 | 0.010 | 1.108 | 1.025 | 1.198 |
| Education | 0.882 | 0.193 | 20.809 | < 0.001 | 2.415 | 1.653 | 3.527 | |
| Economic | 0.683 | 0.286 | 5.704 | 0.017 | 1.980 | 1.130 | 3.470 | |
| Family member size | 0.906 | 0.352 | 6.633 | 0.010 | 2.475 | 1.242 | 4.932 | |
| Health insurance | 0.991 | 0.482 | 4.232 | 0.040 | 2.693 | 1.048 | 6.920 | |
| Family history of PCa | 1.900 | 0.564 | 11.339 | 0.001 | 6.687 | 2.213 | 20.209 | |
| Constant | −14.131 | 3.054 | 21.405 | < 0.001 | < 0.001 | |||
Bivariate correlation between predictor determinants of HBM
| Determinants | Mean (SD) | Range | X1 | X2 | X3 | X4 | X5 |
|---|---|---|---|---|---|---|---|
| X1. Perceived susceptibility | 10.39 (2.22) | 3–15 | 1 | ||||
| X2. Perceived severity | 17.39 (3.36) | 5–25 | 0.515** | 1 | |||
| X3. Perceived benefits | 13.83 (3.46) | 4–20 | 0.435** | 0.254** | 1 | ||
| X4. Perceived barriers | 9.95 (3.37) | 4–20 | −0.417** | −0.329** | −0.119* | 1 | |
| X5. Perceived self-efficacy | 9.56 (2.23) | 3–15 | 0.340** | 0.244** | 0.186** | −0.443** | 1 |
| X6. Cues to action | 1.16 (1.36) | 0–4 | 0.384** | 0.281** | 0.209** | −0.325** | 0.254** |
** P < 0.01 *P < 0.05
Multiple logistic regression analysis for determinants of HBM related to PSA test uptake
| B | S.E. | Wald | P | OR | 95% C.I | ||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Benefits | 0.187 | 0.063 | 8.818 | 0.003 | 1.205 | 1.066 | 1.364 |
| Barriers | −0.073 | 0.070 | 1.091 | 0.296 | 0.930 | 0.810 | 1.066 |
| Susceptibility | −0.261 | 0.140 | 3.500 | 0.061 | 0.770 | 0.585 | 1.013 |
| Severity | 0.223 | 0.091 | 6.044 | 0.014 | 1.249 | 1.046 | 1.492 |
| Self-efficacy | 0.008 | 0.078 | 0.010 | 0.921 | 1.008 | 0.865 | 1.175 |
| Cues to action | 0.707 | 0.134 | 27.876 | < 0.001 | 2.029 | 1.560 | 2.638 |
| Benefits | 0.187 | 0.063 | 8.936 | 0.003 | 1.206 | 1.067 | 1.364 |
| Barriers | −0.075 | 0.067 | 1.277 | 0.258 | 0.928 | 0.814 | 1.057 |
| Susceptibility | −0.261 | 0.139 | 3.495 | 0.062 | 0.771 | 0.586 | 1.013 |
| Severity | 0.223 | 0.090 | 6.069 | .014 | 1.250 | 1.047 | 1.492 |
| Cues to action | 0.708 | 0.134 | 28.128 | < 0.001 | 2.031 | 1.563 | 2.639 |
| Benefits | 0.175 | 0.061 | 8.230 | 0.004 | 1.191 | 1.057 | 1.343 |
| Susceptibility | −0.217 | 0.133 | 2.665 | 0.103 | 0.805 | 0.620 | 1.045 |
| Severity | 0.229 | 0.090 | 6.448 | 0.011 | 1.258 | 1.054 | 1.502 |
| Cues to action | 0.745 | 0.131 | 32.284 | < 0.001 | 2.106 | 1.629 | 2.723 |
| Benefits | 0.125 | 0.052 | 5.864 | 0.015 | 1.133 | 1.024 | 1.253 |
| Severity | 0.131 | 0.063 | 4.325 | 0.038 | 1.140 | 1.008 | 1.290 |
| Cues to action | 0.677 | 0.123 | 30.270 | < 0.001 | 1.967 | 1.546 | 2.504 |